SELENA+, the state-of-the-art artificial intelligence (AI) tool by Nova MSC Bhd, a home-grown software development and engineering solutions provider, has been selected for Oman’s national diabetic retinopathy (DR) screening programme.
This significant step underscores the global recognition and trust in Nova MSC’s EyRIS’s AI-driven solutions for enhancing healthcare outcomes.
A pioneering AI technology, SELENA+ has shown remarkable efficiency and accuracy in automated retinal image analysis.
Its integration into Oman’s healthcare framework marks a major leap forward in managing and preventing diabetes-related complications, particularly diabetic retinopathy. Such initiative signifies Nova MSC’s first venture into Oman and aligns with Malaysia’s commitment to adopting advanced healthcare solutions.
“This collaboration marks a significant milestone in our journey towards revolutionising healthcare with AI technology,” commented Nova MSC’s executive director Nazeroll Kasim.
“SELENA+’s selection is a testament to its technological prowess and our team’s dedication to creating solutions that make a real difference in people’s lives. We are eager to see how our technology will help in the early detection and management of diabetic retinopathy, hence contributing to better health outcomes in Oman.”
SELENA+’s success in Oman follows Nova MSC’s groundbreaking achievements in Singapore’s National DR Screening Programme (SiDRP). In September 2020, EyRIS was awarded a five-year contract for SELENA+ deployment, making it the world’s first real-world AI medical device adoption in a national screening programme.
As an advanced artificial intelligence tool, SELENA+ exhibits the capability to identify vision-threatening diabetic retinopathy, potential glaucoma cases, and age-related macular degeneration. Notably, the accuracy of SELENA+ aligns closely with the established standard of care.
“By taking the lead in the respective ASEAN and Middle East regions, these successes demonstrate our ability to harness advanced technology in tackling global healthcare challenges and serve as springboard to other aspiring countries,” asserted Nazeroll.
“The Oman project exemplifies our significant business-to-government engagement and positions Nova MSC as a leader in AI healthcare innovation. This initiative serves as a model for future collaborations where our technologies can integrate into national healthcare strategies, showcasing our dedication to advancing global healthcare technology.”
At the close of today’s trading, Nova MSC was unchanged at 11 sen with 238,100 shares traded, thus valuing the company at RM131 mil. – Dec 12, 2023